Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
CA 2463676 A1 · Owner: Pastrak, Aleksandra · Inventors: Pastrak, Aleksandra; Turley, Eva A.; Cruz, Tony
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides compositions and methods for treating disorders associated with a response-to-injury process or proliferating cells in a mammal. These tissue disorders are associated with a novel cellular phenotype designated as "transition cells" which are described herein This cellular , phenotype is characterized in having an activated erk kinase signaling activity, a stimulated AP-l binding activity and at least one characteristic , selected from the group consisting of: (a) increased podosome formation (b) , increased flux of intracellular or extracellular hyaluronans or hyaladherins (c) increased expression of a hyaladherin (d) an inability to form focal , adhesions …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 15, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.